Ferrer Internacional S.A. (Ferrer Grupo), Barcelona, Spain
Research Article
Single Dose Bioequivalence Study of Two Rivaroxaban Tablet Formulations, Administered Orally after Being Crushed and Suspended in Apple Puree
Author(s): Simona Nicoleta Duna*, Adrian Ghita, Adelina Ciuciuleaca, Irene Manzanera, David Puibert and Simona Rizea-Savu
The bioavailability of an active substance might be altered when a solid oral dosage form (SODF) is crushed or disintegrated and
mixed with fluids or food in order to assist swallowing. In consequence, the current European Medicines Agency (EMA) practice is to
request comparative bioavailability testing for bridging safety and efficacy data from a formulation administered whole to the same
product administered crushed. Specific criteria for waiving in vivo testing of crushed products are available only for BCS Class I and
Class III drugs. Since rivaroxaban is a Class II drug which can be administered crushed and mixed with fluids, any generic formulation
has to be tested against the originator in this setting. Therefore, an open label, randomized, single dose, two-period, two-sequence,
crossover bioequivalence study with administration of rivaroxaban 10 mg crushed ta.. View more»